Background: Histaminolytic activity mediated by diamine oxidase (DAO) is present
| INTRODUCTION
Diamine oxidase (DAO) was first described almost 90 years ago because of its histamine degradation activity. 1, 2 In humans, high DAO mRNA and activity are found in the gastrointestinal tract, kidney, and placenta. 3 Expression in the placenta is restricted to extravillous trophoblast cells and therefore of fetal and not as assumed for decades of maternal origin. 4 Plasma DAO concentrations increase at least 100-fold during pregnancy, 5 but the physiological function of this rise is not clear.
The high DAO expression in the gastrointestinal tract might protect from histamine present in contaminated food or generated by bacteria within the gut microbiome. Inactivation of DAO using aminoguanidine in pigs and sheep followed by exogenous histamine challenge strongly supports this protection mechanism. 6, 7 Does DAO have any protective function against endogenously released histamine after mast cell (MC) or basophil activation?
Mastocytosis is characterized by an increased number of MCs in various organ systems. 8, 9 Consequently, tryptase and histamine concentrations are elevated and tryptase levels correlate with MC burden. [10] [11] [12] Histamine, its metabolites, and tryptase concentrations rapidly increase during anaphylaxis and are used in the differential diagnosis of MC activation and mast cell activation syndromes (MCAS). [13] [14] [15] [16] [17] [18] Increased serum/plasma tryptase concentrations are caused by liberation from MCs and not basophils, which contain equal amounts of histamine but more than 100-fold less tryptase. 19 Nevertheless, in more than a third of subjects during anaphylaxis, tryptase concentrations measured within 1-2 hours after onset of symptoms were not increased defined as levels > 11.4 ng/mL.
Tryptase levels were increased in 76% of severe anaphylaxis patients. 20 Nevertheless, absolute values above >11.4 ng/mL tryptase and not a relative increase above baseline were used to calculate the percentage of patients with increased tryptase concentrations. Basal serum tryptase levels are also elevated in familial hypertryptasemia with symptomatic or asymptomatic course and in a small percentage of non-anaphylaxis and non-mastocytosis subjects. [21] [22] [23] [24] Histamine is also used as a biomarker of MC degranulation, but the plasma concentrations decline rapidly limiting the usefulness of histamine as indicator of MC activation. 14, 16 Additional markers to measure MC activation might be clinically helpful for differential diagnosis of histamine-like symptoms or anaphylaxis. If MC mediator release can be firmly established, secondary prevention strategies like trigger avoidance or desensitization might be implemented. 25 Heparin is released during MC degranulation. Bleeding complications during anaphylaxis and in patients with systemic mastocytosis have been assigned to released heparin or heparin-like substances. [26] [27] [28] [29] Liberation of DAO by exogenous high molecular weight heparin into blood plasma has been shown in many vertebrates including humans. [30] [31] [32] [33] [34] [35] The rational hypothesis, how MC activation could lead to DAO release, is supported by animal studies after induction of severe anaphylaxis. Mast cell degranulation leads to release of heparin, which is liberating DAO from the storage sites in the gastrointestinal tract in rats and rabbits and in the liver in guinea pigs. [36] [37] [38] [39] [40] [41] Most of these animal studies induced severe anaphylaxis with high mortality questioning the relevance for the majority of human non-fatal hypersensitivity reactions. We did not find any publication showing increased DAO concentrations during anaphylaxis in humans.
G R A P H I C A L A B S T R A C T
Diamine oxidase (DAO) antigen increases more than 100-fold in plasma during severe anaphylaxis and degrades histamine (HIS) in vivo and in vitro but its activity is reduced compared to DAO in pregnancy plasma. Only immediate DAO inhibition after blood withdrawal allows accurate histamine measurements in plasma. Determination of DAO antigen levels might help to diagnose mast cell (MC) activation.
In this study, we wanted to test whether DAO is released during severe anaphylaxis in humans and to demonstrate that the resulting concentrations of DAO are able to degrade histamine possibly mitigating the potential life-threatening effects of high circulatory histamine concentrations. If the measured DAO levels are able to degrade histamine, published histamine concentrations measured during the course of anaphylaxis might be underestimated, because DAO will degrade histamine ex vivo after blood withdrawal, plasma preparation, and downstream activities. Immediate inactivation of DAO after blood withdrawal was considered mandatory for reliably measuring histamine concentrations after induction of anaphylactic shock in animal experiments. 42 2 | MATERIALS AND METHODS
| Human diamine oxidase ELISA
The development and characterization of the human DAO ELISA was recently published in detail. 4, 43 We tested two commercially available DAO ELISA kits but they were not reliable to measure human DAO. 43 
| Tryptase ELISA
Total serum tryptase concentrations were measured by the commercial fluoroimmunoenzyme assay (Thermo Scientific, Uppsala, Sweden)
in the clinical chemistry laboratory of the Vienna General Hospital using an accredited procedure. The detection limit of the assay is 1 ng/mL, and the coefficient of variation (CV) is 4.5% at 9 ng/mL.
| Measurement of histamine concentrations using a histamine ELISA
Histamine concentrations were measured using a histamine ELISA (Immunotech IM2562; Beckman Coulter, Vienna, Austria) and an inhouse development LC-MS/MS method. The LC-MS/MS method was developed, because the histamine ELISA can demonstrate considerable variability at histamine concentrations above 10 ng/mL.
| Measurement of histamine concentrations using LC-MS/MS
A detailed description of this method has been recently published. 4 
| Histamine degradation assay
Histamine degradation rates were determined by incubating serum or plasma samples with 100 ng/mL (900 nmol/L) histamine base for various durations at 37°C. There is no obvious difference using plasma or serum. The reactions were stopped at different time points by adding a final concentration of 50 μmol/L diminazene aceturate (Sigma, D7770, Vienna, Austria). Diminazene is a potent and selective DAO inhibitor with an inhibition constant K i of 13 nmol/L against rhDAO. 44 The samples were then immediately snap-frozen in liquid nitrogen and stored at −30°C until measurement of histamine concentration using LC-MS/MS and ELISA.
| Mastocytosis study DAOMAST00101
A total of 138 mastocytosis patients were contacted. Forty-four
were not reachable and 51 not interested to participate. Twentynine of the 43 included patients (67%) were diagnosed with indolent systemic mastocytosis (ISM). The diagnosis of all included subjects is listed in Table S1 . The diagnosis of mastocytosis was established according to the criteria provided by the World Health Organization. 45 Inclusion criteria included at least 18 years of age at the time 
| Ethics
The local ethics committee of the Medical University of Vienna 
| Statistical analysis
Only standard statistical procedures have been used.
| RESULTS
In the DAOMAST study, a total of 43 patients with mastocytosis were included and plasma samples were obtained at baseline, after 24 and Cox et al 47 and also considered severe systemic reactions.
The DAO and tryptase concentrations at baseline and of four severe and one mild anaphylaxis events are shown in Figure 1A ,B.
We measured on average an 187-fold increase in DAO concentra- Table 1 ). In the two subjects, the concentrations of both antigens were stable at three measurements during the DAOMAST study period of 48 weeks ( Figure 1A ,B). The mild anaphylaxis event induced only a minor but clearly measurable increase in both enzymes.
During the anaphylaxis events, DAO and tryptase concentrations increased significantly over baseline values. Do these two antigens also positively correlate under non-anaphylaxis conditions? DAO and tryptase concentrations from 36 systemic mastocytosis patients were not correlated ( Figure 2A ; R = 0.077; P = 0.66) suggesting that elevated tryptase concentrations do not lead to increased DAO F I G U R E 1 Diamine oxidase (DAO) and tryptase concentrations increase during anaphylaxis in mastocytosis patients. DAO (A) and tryptase (B) concentrations of citrate plasma samples from four severe and one mild anaphylaxis event were determined in duplicates and the means are presented. A1, A2 and B1, B2 were four severe anaphylaxis events in Patients A and B, respectively, whereas A3 was a mild event in Patient A; baseline values were determined during the DAOMAST mastocytosis study at 0, 24, and 48 wk. C,D, shows the ratios of the enzyme concentrations during the anaphylaxis events to the mean baseline values. The scales are not identical. The inset in (D) presents the data in a comparable scale as in (C). Minutes are calculated from the first blood withdrawal time point. This is not equal with the onset of anaphylaxis symptoms. In Patient A, the time window from onset to severe symptoms is <60 min. For severe anaphylaxis events in Patient B, arrival at the emergency department might be considered start of severe symptoms and then the time from onset of severe symptoms and blood withdrawal is <45 min. Table 1 summarizes the data from Figure 1 . DM, DAOMAST study; min, minutes; wk, weeks concentrations. The mean DAO concentration (1.5 ng/mL) was 20-fold lower compared to the mean tryptase value (30.3 ng/mL; Figure 2A ).
Are DAO concentrations stable in mastocytosis patients or do they significantly fluctuate possibly explaining the increased DAO concentrations during the anaphylaxis events? In Figure 2B , the DAO concentrations from 29 mastocytosis patients are shown at baseline, after 24 and 48 weeks. These data imply that DAO antigen levels are stable in indolent systemic mastocytosis and show only minor variations, which highly unlikely can explain the high DAO antigen levels during the severe anaphylaxis events.
Histamine concentrations at the three baseline visits and during the anaphylaxis events are shown in Figure 3A for Subject A and were not cooled allowing continuous histamine degradation.
Exogenous enzymatic histamine degradation was excluded in event B2 because samples were immediately placed on ice and spiked with a potent DAO inhibitor. Is it possible that released DAO is degrading histamine in vivo but also in vitro (ex vivo) after blood withdrawal? In Figure 3C , DAO concentrations seem to negatively correlate with histamine levels. An exact P-value cannot be calculated with the limited data. Samples were immediately placed on ice only for events B1 and B2. The samples from A1 and A2
were withdrawn at a distant hospital and left for a few hours at room temperature, leaving enough time for DAO to degrade histamine ex vivo. Nevertheless, the data in Figure 3C also imply that DAO at 50-100 ng/mL is not able to efficiently degrade histamine, because histamine concentrations of 10-70 ng/mL were measured.
Histamine and putrescine are the preferred natural substrates for human DAO. Using the substrate concentration with half-maximal velocity K m as indicator for substrate affinity, DAO shows the highest affinity to histamine with a K m of 2.8 μmol/L followed by putrescine with 20 μmol/L. 3 There is a wide range of published K m values with putrescine and histamine as substrates for human DAO. For putrescine and histamine, the range (median) is from 3.4 to 94 (26) and 2.5 to 124 (4.6) μmol/L, respectively (see Table S2 ). There is no real consensus for appropriate K m values using human DAO with either substrate. Nevertheless, the Elmore et al 3 Figure 4A shows the time-dependent histamine degradation of 4 serum and 12 plasma samples from late second-/third-trimester pregnancies after adding 100 ng/mL (900 nmol/L) histamine. We used 100 ng/mL because histamine concentrations during severe anaphylaxis can readily reach this level. 14, 26 The inset of Figure 4A shows the histamine degradation rate derived from the 1st derivative of the histamine degradation curve plotted against the histamine concentration. In the 16 pregnancy samples, the mean (SD) DAO concentration was 125 (45) ng/mL. The mean half-life of histamine in They were measured in duplicates using the Immunotech histamine ELISA. The mean is shown. For event B2, the samples were also measured twice in singlicates using the LC-MS/MS method. The mean (±SEM; n = 2) of the histamine ELISA and LC-MS/MS measurements is shown. In the second severe anaphylaxis event of Patient B, we also withdrew blood into citrate vacutainer tubes containing the potent DAO inhibitor diminazene aceturate. B2 -30 min is a sample not shown in Figure 1 withdrawn by an emergency physician 30 min before the 0 time point presented in Figure 1 . At the 72-h time point, the patient was symptom-free; minutes are calculated from the first blood withdrawal time point. This is not equal with the onset of anaphylaxis symptoms (see Figure 1) . C, Histamine concentrations inversely correlate with DAO levels. The figure shows 12 values from the four independent severe anaphylaxis events with the same symbols corresponding to the same event; D, diminazene aceturate; DM, DAOMAST study; min, minutes; wk, weeks; h, hours samples. The pregnancy-equivalent DAO concentrations and activities of the tested anaphylaxis samples are presented in Tables S5-S7 . Only the DAO levels of 196 and 392 ng/mL were able to relevantly degrade histamine after 30 and 60 minutes, although the pregnancy-equivalent activity was only 16% and 17%, respectively (Figure 4B,C; Tables S5, S6 ). In the same experiment, the eight pregnancy control samples with comparable DAO concentrations degraded histamine to a mean of 3.2 and 2.5 ng/mL after 30 and 60 minutes, respectively ( Figure 4D ; Table S7 ).
These two mastocytosis patients were treated during the severe anaphylaxis events with different medications at high doses but these compounds do not inhibit DAO activity ( Figure S3 ).
| DISCUSSION
The massive release of DAO into the circulation during severe anaphylaxis in mastocytosis patients confirms and extends decades-old published animal data. The DAO concentrations measured in the four severe anaphylaxis events are highly unlikely a result of natural enzyme fluctuations. Table S8 summarizes published DAO activity data after conversion to recombinant human DAO equivalent concentrations from anaphylaxis studies in rats, guinea pigs, and rabbits. ). The filled triangles represent the mean histamine concentrations of two pregnancy sera in the presence of 10 μmol/L diminazene aceturate, a potent human DAO inhibitor. The filled squares show the absence of any histamine degradation using plasma from two healthy volunteers (DAO < 2 ng/mL). Inset, The degradation rate was calculated using the 1st derivative of the above equation (histamine degradation rate (ng/mL/min) = 101.5 * −0.2059 * exp (−0.2059 * Min) ) and plotted against the histamine concentration used for this experiment. The regression line equals histamine degradation rate = 0.2059 * histamine concentration. B, Plasma samples from A1, A2 (both severe anaphylaxis), and A3 (mild) events were spiked with 100 ng/mL histamine and incubated for 30 and 60 min at 37°C (dark and light gray bars, respectively). Histamine was measured using the LC-MS/MS method in duplicates, and the mean with SEM is shown. C, Plasma samples from severe anaphylaxis event B2 were spiked with 100 ng/mL histamine base and incubated for 30 and 60 min (dark and light gray bars, respectively). Histamine was measured in singlicates using the LC-MS/MS method; D, in the same experiment, four pregnancy samples were tested for histamine degradation activity as controls; dark and light gray bars represent 30-and 60-min incubation, respectively; D, diminazene aceturate; P, plasma; Preg, pregnancy; S, serum; min, minutes agreement with human DAO concentrations during pregnancy, after heparin administration, and in non-pregnant subjects (see Table S4 and Ref. 43 ). Schmutzler et al 39 published a 30-fold increase in plasma DAO activity in guinea pigs after induction of severe anaphylaxis. The same group showed increased histaminolytic activity reflected in shortened histamine half-lives in plasma of guinea pigs after induction of anaphylaxis or heparin infusion. 41 Aminoguanidine, a relatively specific, potent irreversible DAO inhibitor, completely blocked histamine breakdown in plasma after induction of anaphylaxis in several animal studies. 37, 38, 40, 41 It is intriguing to speculate that DAO is actually liberated by the heparin/tryptase complex released from MCs in the gastrointestinal tract. 48 A putative heparin-binding site was described for DAO. 44 The animal species. Therefore, it is impossible to assign mortality or severe morbidity in animal studies to a single mediator.
We obviously cannot answer the same question for human anaphylaxis events. The measured histamine concentrations, especially the large drop of histamine in the B2 event combined with the increase of DAO, argue that DAO was degrading histamine in vivo.
Hemodynamic improvement reflected in a normalization of the heart rate coincided with increased DAO levels.
The cause behind the greatly reduced DAO activities during anaphylaxis compared to pregnancy samples must be addressed.
The medications used for the treatment of the severe anaphylaxis cases do not inhibit DAO activity. The lack of appropriate human material is severely limiting these investigations. Nevertheless, recombinant DAO might be administered at high concentrations BOEHM ET AL.
| 591 overcoming the presence of a possible DAO inhibitor or inactivation mechanism.
In conclusion, DAO increases more than 100-fold during severe anaphylaxis in mastocytosis patients and is likely involved in the in vivo and ex vivo degradation of histamine. Measurements of DAO with tryptase during suspected MC activation might increase the rate of correct MCAS diagnosis. Correct determination of histamine levels in samples with high DAO concentrations requires immediate inactivation of DAO after blood withdrawal.
Otherwise, DAO degrades histamine and artifactually low histamine concentrations will be measured. The mechanism causing significantly reduced DAO activity in relation to antigen levels must be investigated. This putative DAO inhibitor might interfere with histamine degradation using recombinant human DAO to treat life-threatening histamine effects during MC activation or severe anaphylaxis.
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